J&J's tuberculosis drug Sirturo wins FDA approval

01/1/2013 | Reuters · MSN

The FDA approved the use of Johnson & Johnson's Sirturo, or bedaquiline, in combination with other drugs, to treat patients with multidrug-resistant tuberculosis. Sirturo, developed by J&J's Janssen Therapeutics, is the first new tuberculosis drug to gain approval in 40 years. Because of the possibility of fatal heart problems, Sirturo will carry a boxed warning.

View Full Article in:

Reuters · MSN

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX